ReWalk Robotics (NASDAQ: RWLK) is one of 26 public companies in the “Surgical appliances & supplies” industry, but how does it contrast to its competitors? We will compare ReWalk Robotics to similar companies based on the strength of its profitability, earnings, dividends, risk, analyst recommendations, institutional ownership and valuation.
Earnings and Valuation
This table compares ReWalk Robotics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ReWalk Robotics||$7.75 million||-$24.71 million||-1.11|
|ReWalk Robotics Competitors||$1.33 billion||$194.17 million||23.46|
This is a breakdown of current ratings and recommmendations for ReWalk Robotics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ReWalk Robotics Competitors||123||705||1254||53||2.58|
ReWalk Robotics presently has a consensus target price of $2.80, suggesting a potential upside of 154.52%. As a group, “Surgical appliances & supplies” companies have a potential upside of 0.27%. Given ReWalk Robotics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe ReWalk Robotics is more favorable than its competitors.
Insider and Institutional Ownership
2.5% of ReWalk Robotics shares are held by institutional investors. Comparatively, 54.5% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 6.9% of ReWalk Robotics shares are held by insiders. Comparatively, 10.4% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares ReWalk Robotics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ReWalk Robotics Competitors||-295.29%||-52.73%||-18.42%|
Risk & Volatility
ReWalk Robotics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, ReWalk Robotics’ competitors have a beta of 0.84, suggesting that their average stock price is 16% less volatile than the S&P 500.
ReWalk Robotics competitors beat ReWalk Robotics on 10 of the 13 factors compared.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. It is also developing ReWalk Restore, a soft suit exoskeleton for individuals who have suffered a stroke. ReWalk Robotics Ltd. markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokne'am Illit, Israel.
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.